Epidemiological data from 2015 showed that approximately 46 million people were affected with dementia worldwide, of which 9.4 million were in the Americas, 10.5 million in Europe, 4 million in Africa, and 22.9 million in Asia. It is estimated that by 2035 these figures could double.
Modern scientific research discovered the endocannabinoid system's protective role with neurodegenerative diseases such as Alzheimer's. The elements through which cannabinoids contribute to minimizing the effect it has on neuronal cells, include cellular mechanisms to regulate the exaggerated inflammatory response, a result of the stimulation of beta-amyloid peptide, and the promotion of the synthesis of degradative enzymes of this substance. Endocannabinoid system stimulation through phytocannabinoids use, such as CBD, promotes neurogenesis (formation of new neurons from precursor cells) and triggers protective mechanisms against free-radical damage. Also, Δ9-THC protects the brain from various neuronal aggressions and ameliorates, both symptoms of neurodegeneration.
As scientific literature becomes available, the link between the endocannabinoid system and the delay in the progression of neurodegenerative diseases, such as Alzheimer's, is more evident. The same thing happens with other beneficial properties, also attributed to cannabinoids use, such as acting as anxiolytics, antidepressants, neuroprotective, orexigenic, memory stimulants, and regulating sleep.
There is great interest in the proposal of medical cannabis as a therapeutic alternative in the management and treatment of Alzheimer's disease. In the future, it could position itself as one of the most effective and safe ways to treat or slow down the degenerative process in this pathology.
